论文部分内容阅读
目的研究胃癌HER-2表达情况与胃癌患者临床病理特征和预后的关系。方法采用免疫组化法(IHC)检测146胃癌患者HER-2的表达情况,统计分析HER-2表达与肿瘤病理分型,分化程度,预后的关系。结果 146例胃癌患者,采用免疫组化法检测HER-2表达,其中35例患者HER-2阳性表达(3+,2+),阳性率24%(35/146),111例胃癌患者HER-2阴性表达(0,1+),阴性率76%(111/146)。没有观察到HER-2阳性表达和阴性表达患者在年龄,性别,PT,N,M因素,肿瘤病理TNM分期方面的差异(P>0.05)。HER-2阳性和HER-2阴性患者的中位总生存期(overall Survival)是12个月和25个月,差异有统计学意义(P<0.01)。结论胃癌患者HER-2阳性率与国外报道相似。HER-2阳性表达患者5年生存率低于HER-2阴性表达患者。
Objective To study the relationship between the expression of HER-2 in gastric cancer and clinicopathological features and prognosis of gastric cancer. Methods Immunohistochemistry (IHC) was used to detect the expression of HER-2 in 146 gastric cancer patients. The relationship between HER-2 expression and tumor pathological type, differentiation degree and prognosis was statistically analyzed. Results The expression of HER-2 was detected by immunohistochemistry in 146 cases of gastric cancer. The positive rate of HER-2 was (3 +, 2 +) in 35 cases, the positive rate was 24% (35/146) 2 negative expression (0,1+), the negative rate of 76% (111/146). No difference was observed in the age, gender, PT, N, M factors, tumor pathological TNM staging between HER-2 positive and negative HER-2 expression (P> 0.05). The median overall survival of HER-2-positive and HER-2-negative patients was 12 months and 25 months, with a statistically significant difference (P <0.01). Conclusion The positive rate of HER-2 in gastric cancer patients is similar to that reported in foreign countries. The 5-year survival rate of HER-2-positive patients is lower than that of HER-2 negative patients.